Dengue Fever Sept.2007 Dr.Wail Bajhmoum

799 views
725 views

Published on

Published in: Travel, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
799
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
21
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Dengue Fever Sept.2007 Dr.Wail Bajhmoum

  1. 1. Kingdom of Saudi Arabia King Fahd Hospital Jeddah Internal Medical Department
  2. 2. Dengue Fever By:  Dr.wail Bajhmoum  Wednesday 21/5/2008 ; 16/5/1429
  3. 3. Background Frequency Race ; Sex and Age
  4. 4. Transmission Mortality/Morbidity Clinical Presentation
  5. 5. Treatment Our hospital statistic
  6. 6. Background Dengue fever–like illnesses were described in Chinese medical writings dating back to 265 AD. In 1789, Benjamin Rush, MD, published an account of a dengue fever epidemic that had occurred in Philadelphia in 1780.
  7. 7. The first epidemic of dengue hemorrhagic fever was described in Manila in 1953.
  8. 8. Frequency Dengue virus causes about 100 million cases of acute febrile disease annually, including more than 500,000 reported cases of DHF/DSS. Currently, dengue is endemic in 112 countries.
  9. 9. Race ; Age and Sex Ethnicity is nonspecific All ages are susceptible.
  10. 10. Both sexes have the same incidence, however, fewer cases have been reported more in men than in women.
  11. 11. Transmission o by mosquito vectors  Aedes aegypti in the sub- tropical and tropical Americas  Aedes albopictus in Asia
  12. 12. Aedes Aegypti the Dengue Vector
  13. 13. Mortality/Morbidity • Treated DHF/DSS is associated with a 3% mortality rate. • Untreated DHF/DSS is associated with a 50% mortality rate.
  14. 14. Clinical Presentation
  15. 15.  Rash– petechial, diffuse erythematous or morbilliform  Hemorrhagic manifestations – epistaxis, petechiae, gum bleeding
  16. 16.  Leukopenia  Thrombocytopenia  Lymphadenopathy
  17. 17.  Breakbone fever  Infectioncan lead to DHF, resulting in renal failure and DSS
  18. 18. Treatment No vaccine available, treatment is supportive
  19. 19. Our hospital statistic
  20. 20. Range of Patie nts Age 21 - 34 Year Patient 10 30 50 Year
  21. 21. % Male Vs. %Female Patients 27% 73%
  22. 22. Positive IgM Vs. Nigative Patients Negative IgM Patients, 28% Positive IgM Patients, 72%
  23. 23. % Saudi Vs . Non Saudi w ith Pos itive IgM Non Saudi Saudi 49% 51%
  24. 24. 4 Months Patients Vs. Total Patients 11 60
  25. 25. %Male Vs. %Female with PositiveIgM Fe m ale 33% M ale 67%
  26. 26. Thank you

×